Psychopharmaceuticals
PreclinicalSmall molecule
Psychopharmaceuticals is one of 14 small molecule programs targeting Borderline personality disorder. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Borderline Personality Disorder
#DrugCompanyPhaseTrials
1Celexa
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Tylenol
KKenvue Brands
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Psilocybin
COMPASS PathwaysPhase 2
Florinef
Jazz PharmaceuticalsPreclinical
Depakote
TevaPreclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Selincro
IIndivior Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Psychopharmaceuticals. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFrancisco Miguel Correia Sampaio